Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 26;12(2):220. doi: 10.1038/s41419-021-03511-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Western blot showed that expression and distribution of TFE3 was dynamic between the nucleus and the cytoplasm. GAPDH and Histone served as specific internal reference markers for cytoplasm and nuclei respectively. b The target genes of TFE3 were verified in786O/OE-SR cells treated with DMSO or sunitinib (10 μM) for 12 h. Data are shown as means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, NS: not significant. Data were obtained from three independent experiments. c After knocking down of TFE3, qPCR verified the target gene of TFE3 in 786 O/OE-SR cells treated with DMSO, sunitinib (10 μM) for 12 h. **P < 0.01, ***P < 0.001. Data are shown as means ± SD (n = 3). d Proteins downstream of TFE3 in 786 O/OE-SR cell line were upregulated with the increase in sunitinib concentration. e After knocking down of TFE3, 786 O/OE-SR were treated with sunitinib (10 μM) for 12 h cells and proteins downstream of TFE3 were down regulated. f Transwell assay to assess migration after 12 h incubation of 786 O/OE-SR with different concentration of sunitinib compared with 786 O/OE cells. Scale bar, 200 μm, ***P < 0.001, **P < 0.01, *P < 0.05, NS: not significant. Data are shown as means ± SD (n = 3). g Transwell assay to assess invasion after 12 h incubation of 786 O/OE-SR with different concentration of sunitinib compared with 786 O/OE cells. Scale bar, 200 μm. **P < 0.01, ***P < 0.001. Data are shown as means ± SD (n = 3). h Wound healing assays for 786 O/OE and 786 O/OE-SR cells with DMSO, sunitinib (10 μM) for 24 h. Scale bar, 250 μm. *P < 0.05, **P < 0.01, NS: not significant. Data are shown as means ± SD (n = 3). i Rescue experiments showed that knockout of TFE3 could reverse the effect of sunitinib on tumor metastasis in 786 O/OE-SR cells. Scale bar, 200 μm, *P < 0.05, **P < 0.01, NS: not significant. Data are shown as means ± SD (n = 3).